Rhodes Linda
Board of Directors, Alliance for Contraception in Cats & Dogs (ACC&D), Portland, Oregon, USA
J Feline Med Surg. 2015 Sep;17(9):783-9. doi: 10.1177/1098612X15594993.
Non-surgical contraceptives or sterilants need regulatory approval to be sold for that use. This approval process gives veterinarians the information required to assess the benefits and risks of each product, and to provide comprehensive information on the required dose, method and duration of use, safety and effectiveness.
This article reviews the information that must be developed and provided to regulatory agencies worldwide, with a focus on the European Union and the United States, in order to achieve regulatory approval.
The main components of developing a drug include developing extensive information on the safety and effectiveness of the product, and also the safety to the environment and to humans handling and administering the drug. Most importantly, a robust method of manufacturing both the drug itself and the formulated drug product (pill, liquid implant or injection) must be developed to assure quality and consistency in each batch. This information is then compiled and submitted to regulatory agencies; in the United States, this includes the Food and Drug Administration, the United States Department of Agriculture and the Environmental Protection Agency, and, in Europe, the European Medicines Agency.
Because of the unique nature of non-surgical contraceptives for use in cats and dogs, particularly the desire to have these products last over multiple years, there are special challenges to their regulatory approval that are discussed in this review.
非手术避孕药物或绝育剂若要作为此类用途销售,需获得监管部门批准。这一审批过程能为兽医提供评估每种产品的益处和风险所需的信息,以及关于所需剂量、使用方法和持续时间、安全性和有效性的全面信息。
本文回顾了为获得监管批准必须向全球监管机构(重点是欧盟和美国)提供的信息。
研发一种药物的主要组成部分包括获取有关该产品安全性和有效性的广泛信息,以及对环境和处理及施用该药物的人员的安全性信息。最重要的是,必须研发出一种生产药物本身以及制成药物产品(药丸、液体植入剂或注射剂)的可靠方法,以确保每一批产品的质量和一致性。然后将这些信息整理并提交给监管机构;在美国,这包括食品药品监督管理局、美国农业部和环境保护局,在欧洲,则是欧洲药品管理局。
由于用于猫和狗的非手术避孕药物的独特性质,尤其是希望这些产品能持续多年使用,其监管批准存在特殊挑战,本文对此进行了讨论。